OHSS Risk With PCOS: The Symptoms That Mean Emergency Care

Why Does PCOS Raise OHSS Risk So Much?

Ovarian hyperstimulation syndrome starts when an ovary responds to fertility medication with far more developing follicles than intended, then releases vascular endothelial growth factor and related substances that make blood vessels leak fluid out of general circulation. That fluid collects in the abdomen, and in more severe cases around the lungs — the mechanical basis for nearly every symptom on this page, from bloating to breathlessness.

A 2015 systematic review of OHSS prediction methods identified antral follicle count and anti-Müllerian hormone (AMH) as the two strongest predictors of a high ovarian response, and a high response itself — measured by follicle number, estradiol level, or oocytes retrieved — as the best predictor of OHSS (Nastri et al., 2015). Both of those top predictors are the same two markers that run structurally high in PCOS. That is exactly why PCOS functions as a genuine risk factor rather than a coincidence: an ovary carrying a large resting pool of small follicles has more raw material to overrespond with once gonadotropin stimulation starts.

That mechanism is specific to ovarian stimulation, not to PCOS by itself. A cycle that never stimulates the ovaries with injectable gonadotropins — a natural cycle, or oral ovulation induction alone — cannot trigger the same cascade at anything close to the same scale, a distinction covered in more detail further down this page.

How Common Is OHSS, and How Severe Does It Get?

Mild OHSS is common enough to count as an expected side effect of ovarian stimulation rather than a rare complication: an American Society for Reproductive Medicine (ASRM) patient fact sheet puts it at roughly one in three people undergoing controlled stimulation for IVF, with symptoms limited to bloating, nausea, and fluid-related weight gain (ASRM, 2023). Moderate or severe forms are far less common — a 2021 Cochrane review pooling 3,171 women at elevated OHSS risk put the combined moderate-or-severe rate at 3% to 8% of IVF cycles (Tang et al., 2021) — and severe OHSS specifically has long been estimated at 0.5% to 5% of stimulated cycles across the wider literature (Delvigne & Rozenberg, 2002).

PCOS moves those numbers substantially. A prospective cohort of 290 women under 37 having their first IVF cycle found severe OHSS requiring hospitalisation in 15.4% of women with PCOS, against 2.7% of women with normal ovarian morphology — nearly a six-fold difference inside the same clinic, using the same protocols (Swanton et al., 2010). That gap is the practical reason PCOS is treated as the single most consistent risk factor for OHSS in fertility medicine, not a footnote limited to a subset of cases.

What’s the Difference Between Early-Onset and Late-Onset OHSS?

OHSS comes in two forms that behave differently enough to need separate names, and only one of them has anything to do with whether a pregnancy is present. A study designed specifically to distinguish the two found that early OHSS tracks the ovaries’ immediate response to stimulation — higher estradiol, lower gonadotropin requirement — while late OHSS “depends on the occurrence of pregnancy…and is only poorly related to preovulatory events” (Mathur et al., 2000). In that same study, every cycle with late OHSS had resulted in a clinical pregnancy, and late OHSS was more likely than early OHSS to become severe.

The practical implication is a timeline most patient materials leave out. Early OHSS symptoms typically appear within days of egg retrieval and, without a pregnancy, usually resolve within about two weeks. If pregnancy does occur, symptoms often continue for two to three weeks or longer past a positive test, because the pregnancy’s own rising hCG re-stimulates an ovary that was already primed to overrespond (ASRM, 2023).

What Are the Red-Flag Symptoms, and Which Ones Mean Emergency Care?

The second tier of that table is emergency-only for a specific reason: the mechanisms that make severe OHSS life-threatening are exactly what those symptoms describe. Breathlessness signals fluid displacing lung capacity; calf pain, swelling, or redness signals the clotting risk that comes with a fluid-shifted, concentrated bloodstream — the venous thromboembolism risk that ASRM’s 2024 prevention guideline names as a defining complication of severe cases (ASRM Practice Committee, 2024). Neither of those improves by waiting to see if it passes.

Does Oral Ovulation Induction Carry the Same Risk as IVF?

No — and the gap is large enough to change what “OHSS risk” actually means depending on which treatment is happening. In the pivotal trial comparing letrozole with clomiphene for ovulation induction in PCOS, OHSS occurred at an identical, low 0.5% rate in both drug groups (Franik et al., 2022) — both oral drugs work by prompting the body’s own, self-limited FSH release, which caps how far the ovarian response can run. Injectable ovulation induction — a lower-dose approach aimed at maturing one or two follicles rather than the many an IVF retrieval needs — carries a different, intermediate profile, covered in full on this site’s dedicated page on gonadotropin injections. IVF-level stimulation is where risk climbs into the ranges in Table 1, precisely because it deliberately recruits far more follicles than either oral drugs or lower-dose injectable induction ever attempt to.

What Actually Lowers OHSS Risk, According to the Trials?

Four interventions have randomized trial evidence behind them, and each addresses a different point in the mechanism described above. A GnRH-antagonist stimulation protocol lowered OHSS of any grade from an estimated 11% to between 6% and 9%, without reducing live birth, across 73 trials and over 12,000 women (Al-Inany et al., 2016). Switching the final trigger injection from hCG to a GnRH agonist lowered moderate-or-severe OHSS from an estimated 5% to between nil and 2% — but only in fresh cycles, and only at a real cost: live birth fell from roughly 31% to between 12% and 24% in that same comparison, a trade-off that disappeared in donor-egg and freeze-all cycles, where no fresh pregnancy follows the same stimulated ovary (Youssef et al., 2014). Dopamine agonists — cabergoline, quinagolide, or bromocriptine, started after egg retrieval — lowered moderate-or-severe OHSS from an estimated 27% to between 8% and 14% in a pooled analysis of 22 trials and 3,171 high-risk women, with no clear effect on live birth rates in either direction (Tang et al., 2021). And in PCOS specifically, freezing every embryo instead of a fresh transfer cut OHSS from 7.1% to 1.3% in the largest PCOS-specific randomized trial available, by removing the late-onset pathway described earlier — no pregnancy landing on an already-stimulated ovary in the same cycle (Chen et al., 2016).

None of this is a menu to request. Which combination of protocol, trigger, and transfer timing fits a specific ovarian reserve, stimulation response, and treatment history is exactly the decision a fertility clinic makes before stimulation starts, using antral follicle count and AMH results this page does not have. The numbers above describe what trials found, not what any individual cycle should do.

Who Is Most at Risk, and What Doesn’t This Cover?

High AMH and PCOS are the two risk factors ASRM’s own patient guidance names specifically — and the same guidance states plainly that people with low ovarian reserve are not at meaningfully increased risk, worth knowing if OHSS worry is being carried into a cycle where it doesn’t apply (ASRM, 2023). Risk also depends on which treatment is actually happening: someone on oral letrozole or clomiphene alone, or having in vitro maturation instead of full ovarian stimulation, is not carrying IVF-level risk, even with a PCOS diagnosis. And an elective egg-freezing cycle carries the same stimulation-driven risk as an IVF cycle right up through retrieval, even though no embryo transfer follows it.

This page covers recognition and escalation — which symptoms mean what, and when to act — not how OHSS itself gets treated once it is confirmed. Fluid drainage, IV fluids, and any hospital admission are clinical decisions made in person by the treating clinic, not something a symptom list can settle. For the wider PCOS fertility picture beyond this one complication, PCOSguides’ fertility section covers ovulation induction, IVF, and the other treatment pathways from the start.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Every figure on this page applies under either name — only the label changed, and this page uses PCOS because that is still what most readers search.